Elevated Lipoprotein(a)
3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Ionis PharmaceuticalsCARLSBAD, CA
3 programs1
2
ISIS 681257Phase 21 trial
ISIS-APOPhase 21 trial
IONIS-APOPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Ionis PharmaceuticalsISIS 681257
Ionis PharmaceuticalsISIS-APO
Ionis PharmaceuticalsIONIS-APO
Clinical Trials (3)
Total enrollment: 410 patients across 3 trials
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
Start: Mar 2017Est. completion: Nov 2018286 patients
Phase 2Completed
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)
Start: Jun 2014Est. completion: Nov 201564 patients
Phase 2Completed
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)
Start: Apr 2015Est. completion: Feb 201660 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space